Figure 7.

miR-203a-3p Inhibits HSC Proliferation by Targeting p66Shc

(A–D) miR-203a-3p (A), p66Shc (B), phosphorylated β-catenin and β-catenin (C), and α-SMA and COL1A2 (D) expression in LX-2 cells from different groups. LX-2 cells were treated with CA, PDGF-BB, ango-miR-203a-3p control, ango-miR-203a-3p, or nothing; n = 3. ∗∗p < 0.01 versus the control group; ##p < 0.01 versus the PDGF-BB group. (E–H) CCK8 assay results (E) and the p66Shc and cyclin D1 (F), phosphorylated β-catenin and β-catenin (G), and α-SMA and COL1A2 (H) protein expression levels in LX-2 cells. LX-2 cells were treated with PDGF-BB, ango-miR-203a-3p control, ango-miR-203a-3p, target protector-p66Shc, or nothing; n = 3. ∗∗p < 0.01 versus the control group; #p < 0.05 versus the PDGF-BB group; ##p < 0.01 versus the PDGF-BB group; &p < 0.05 versus the ango-miR-203a-3p group; &&p < 0.01 versus the ango-miR-203a-3p group. (I and J) The percentage of LX-2 cells in the G1 phase; n = 3. ∗∗p < 0.01 versus the control group; #p < 0.05 versus the PDGF-BB group; &p < 0.05 versus the ango-miR-203a-3p group.